Brian R Edlin1. 1. National Development and Research Institutes, New York, NY 10010, USA. bredlin.nyc@gmail.com
Abstract
UNLABELLED: Hepatitis C is the most prevalent bloodborne viral disease in the United States and the deadliest. This year, the U.S. Preventive Services Task Force (USPSTF) will update its 2004 hepatitis C guideline, which recommends against screening asymptomatic adults for hepatitis C. This guideline has hampered public health efforts to encourage screening and identify and refer infected persons for care by declaring that such interventions were not supported by the evidence. A draft revision of the guideline, released on November 26, 2012, concludes that testing persons born between 1945 and 1965 probably has at least a small net benefit, but stops short of definitively recommending that this cohort be screened. This article examines the Task Force's process for writing its guidelines. It recommends that the Task Force adopt a balanced approach to evaluating the benefits and harms of screening; use the preponderance of the evidence as a standard for evaluating interventions that target serious public health problems; be transparent about the value judgments that go into its decisions; consider the wide variation in disease prevalence in diverse patient populations; and recommend screening asymptomatic adults for hepatitis C. CONCLUSION: By taking a broader view of the evidence, the Task Force can write new guidelines that will serve efforts to curb the hepatitis C epidemic, rather than frustrate them.
UNLABELLED: Hepatitis C is the most prevalent bloodborne viral disease in the United States and the deadliest. This year, the U.S. Preventive Services Task Force (USPSTF) will update its 2004 hepatitis C guideline, which recommends against screening asymptomatic adults for hepatitis C. This guideline has hampered public health efforts to encourage screening and identify and refer infected persons for care by declaring that such interventions were not supported by the evidence. A draft revision of the guideline, released on November 26, 2012, concludes that testing persons born between 1945 and 1965 probably has at least a small net benefit, but stops short of definitively recommending that this cohort be screened. This article examines the Task Force's process for writing its guidelines. It recommends that the Task Force adopt a balanced approach to evaluating the benefits and harms of screening; use the preponderance of the evidence as a standard for evaluating interventions that target serious public health problems; be transparent about the value judgments that go into its decisions; consider the wide variation in disease prevalence in diverse patient populations; and recommend screening asymptomatic adults for hepatitis C. CONCLUSION: By taking a broader view of the evidence, the Task Force can write new guidelines that will serve efforts to curb the hepatitis C epidemic, rather than frustrate them.
Authors: Ira M Jacobson; Patrice Cacoub; Luigino Dal Maso; Stephen A Harrison; Zobair M Younossi Journal: Clin Gastroenterol Hepatol Date: 2010-09-24 Impact factor: 11.382
Authors: Christopher J Sonnenday; Justin B Dimick; Richard D Schulick; Michael A Choti Journal: J Gastrointest Surg Date: 2007-10-03 Impact factor: 3.452
Authors: Lisa I Backus; Derek B Boothroyd; Barbara R Phillips; Pamela Belperio; James Halloran; Larry A Mole Journal: Clin Gastroenterol Hepatol Date: 2011-03-11 Impact factor: 11.382
Authors: David B Rein; John S Wittenborn; Cindy M Weinbaum; Miriam Sabin; Bryce D Smith; Sarah B Lesesne Journal: Dig Liver Dis Date: 2010-06-17 Impact factor: 4.088
Authors: Christine M Rousseau; George N Ioannou; Jeffrey A Todd-Stenberg; Kevin L Sloan; Meaghan F Larson; Christopher W Forsberg; Jason A Dominitz Journal: Am J Public Health Date: 2008-04-01 Impact factor: 9.308
Authors: Carla V Rodriguez; Kevin B Rubenstein; Benjamin Linas; Haihong Hu; Michael Horberg Journal: Am J Manag Care Date: 2018-05-01 Impact factor: 2.229
Authors: Roland C Merchant; Janette R Baird; Tao Liu; Lynn E Taylor; Brian T Montague; Ted D Nirenberg Journal: Acad Emerg Med Date: 2014-07 Impact factor: 3.451
Authors: V Saxena; M M Manos; H S Yee; L Catalli; E Wayne; R C Murphy; V A Shvachko; M P Pauly; J Chua; A Monto; N A Terrault Journal: Aliment Pharmacol Ther Date: 2014-03-24 Impact factor: 8.171
Authors: Amit G Singal; Tushar D Dharia; Peter F Malet; Saleh Alqahtani; Song Zhang; Jennifer A Cuthbert Journal: BMJ Open Date: 2013-09-03 Impact factor: 2.692
Authors: Dennis G Fisher; Kristen L Hess; Erlyana Erlyana; Grace L Reynolds; Catherine A Cummins; Todd A Alonzo Journal: Open Forum Infect Dis Date: 2015-07-07 Impact factor: 3.835
Authors: James G Carlucci; Syeda A Farooq; Lindsey Sizemore; Michael Rickles; Brandon Cosley; Leigh McCormack; Carolyn Wester Journal: PLoS One Date: 2017-11-30 Impact factor: 3.240
Authors: Coralie Hermetet; Frederic Dubois; Catherine Gaudy-Graffin; Yannick Bacq; Bernard Royer; Christophe Gaborit; Louis D'Alteroche; Jean Claude Desenclos; Philippe Roingeard; Leslie Grammatico-Guillon Journal: PLoS One Date: 2017-08-29 Impact factor: 3.240